Quarterly report pursuant to Section 13 or 15(d)

Collaborative Arrangements - Platform Technology Transfer and License Agreement (Details)

v3.20.2
Collaborative Arrangements - Platform Technology Transfer and License Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Jun. 30, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contract with customer, liability   $ 4,056   $ 4,056     $ 2,044
Revenue recognized   18,385 $ 21,906 48,023 $ 49,808    
Novartis [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Term of collaborative research and development agreement 23 months            
Contract with customer, liability $ 5,000            
Revenue recognized   $ 900 $ 3,800 $ 4,100 $ 3,800    
Novartis [Member] | Royalty [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Term of collaborative research and development agreement 23 months            
Novartis [Member] | Computer Equipment and Software [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent annual receivable increase $ 8,000            
Novartis [Member] | Milestone One [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent receivable           $ 4,000  
Novartis [Member] | Milestone Two [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent receivable $ 5,000